Koth Valesca Sander, Figueiredo Maria Antonia, Salum Fernanda Gonçalves, Cherubini Karen
1 Post-Graduate Program, Dental College, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.
Dentomaxillofac Radiol. 2016;45(7):20160049. doi: 10.1259/dmfr.20160049. Epub 2016 May 31.
The present work aimed to review the literature focusing on the diagnostic criteria for bisphosphonate-related osteonecrosis of the jaw (BRONJ) and its implications regarding the management of the disease. Since the report of the first cases, BRONJ concepts, diagnostic criteria and guidelines have been changed. The presence of bone exposure in the oral cavity was at first a sine qua non condition for diagnosis. However, it seems that the great concern now is the possibility of occurrence of BRONJ without this feature. Some authors warn that the bone exposure criterion leads to late diagnosis and poor response to treatment. Meanwhile, some radiographic features, such as bone sclerosis, have been postulated as early signs of the disease. Criticisms have also been raised about the clinical staging system of BRONJ. While there is no consensus on the subject, common sense recommends treating symptomatic patients taking bisphosphonate as having BRONJ despite the absence of bone exposure; and asymptomatic patients must be kept under dental follow-up, since all of them are at risk for BRONJ.
本研究旨在回顾聚焦于双膦酸盐相关颌骨坏死(BRONJ)诊断标准及其疾病管理意义的文献。自首例病例报告以来,BRONJ的概念、诊断标准和指南已发生变化。口腔内骨暴露起初是诊断的必要条件。然而,现在似乎人们极为关注的是无此特征时发生BRONJ的可能性。一些作者警告说,骨暴露标准会导致诊断延迟和治疗反应不佳。同时,一些影像学特征,如骨硬化,已被假定为该疾病的早期迹象。对于BRONJ的临床分期系统也提出了批评。虽然在这个问题上没有达成共识,但常识建议,尽管没有骨暴露,对于正在服用双膦酸盐的有症状患者应视为患有BRONJ进行治疗;而无症状患者必须接受牙科随访,因为他们所有人都有患BRONJ的风险。